T cells are the immune system’s frontline fighters. When they detect danger, they rapidly multiply and transform into ...

The deal gives Cullinan T cell engagers aimed at BCMA and CD19, which drugmakers are exploring as possible targets for ...

Celiac disease frustratingly restrictive, the only real medical intervention for sufferers being to avoid gluten altogether.

Cullinan Therapeutics has announced a licensing agreement with Genrix Bio for global rights to velinotamig, a clinical-stage ...

The Cocoon® (from Lonza) is a functionally closed, sterile, efficient manufacturing platform, which combined with our ...

Findings indicate that frequent COVID-19 booster shots do not weaken T-cell responses, alleviating concerns for vulnerable ...

How CD4+ T cells respond to Chikungunya virus may trigger long-lasting joint pain, mimicking autoimmune disease long after ...

Genrix’s velinotamig complements Cullinan’s own pipeline, according to William Blair, which added that the deal will put ...

Researchers found that immune T cells reside in healthy brains, signaling between the gut and brain, a previously unknown ...

The dual-targeting CAR T-cell therapy KITE-363 showed positive response rates and manageable side effects in relapsed or ...

Adding IL-12 to mRNA vaccines can lead to longer lasting protective effect and a potential approach for reducing the risk of ...

A new study will evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in relapsed or refractory autoimmune diseases including antineutrophil cytoplasmic antibody ...